Heron Therapeutics, INC /DE/ Form 4 insider transactions

William P. Forbes, EVP and Chief Development Officer of Heron Therapeutics, reports the vesting of restricted stock units into common stock.

Heron Therapeutics CEO Craig Collard reports the vesting and subsequent disposal of restricted stock units.

Heron Therapeutics CEO Craig Collard reports the vesting of 62,500 restricted stock units into common stock on April 3, 2024.